BridgeMD
Boosting recovery through excitation of arousal and awareness in comatose patients (BREA2KTHROUGH)
EU CTIS ID: 2023-503617-30-01
What this study is testing
To investigate if psilocybin and apomorphine can improve clinical levels of consciousness (as measured by the FOUR score and the SECONDs)
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinically unresponsive patients admitted to the ICU either with a traumatic or non-traumatic brain injury or a systemic medical or surgical condition causing non-medically induced coma
- Unconsciousness is expected by the attending physicians to last for ≥3 days
- Age ≥18 years
You likely can't join if
- Continuous pharmacologically sedation
- Expected survival <7 days
- Lack of Danish or English language proficiency
- Lack of next-of-kin consent
- Residency outside of Denmark
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.